Loading...
•
Jun 30, 2021
Blueprint Medicines Q2 2021 Earnings Report
Blueprint Medicines' Q2 2021 performance was marked by AYVAKIT's FDA approval for advanced systemic mastocytosis and its successful launch, alongside the progression of the clinical portfolio and strategic collaborations.
Key Takeaways
Blueprint Medicines reported a revenue of $27.3 million for the second quarter of 2021, including $8.5 million from AYVAKIT/AYVAKYT and $2.9 million from GAVRETO. The company's net loss was $108.4 million, or $1.86 per share. They also initiated multiple clinical trials and announced a research collaboration with MD Anderson.
Secured U.S. approval of AYVAKIT for advanced systemic mastocytosis and launched the therapy.
AYVAKIT/AYVAKYT generated $8.5 million in net product revenue.
GAVRETO recorded $2.9 million in net product revenue.
Initiated Phase 1/2 trial of BLU-945 and Phase 2/3 HARBOR trial of BLU-263.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Blueprint Medicines expects to present preclinical data for BLU-945 and BLU-701 in 2H 2021, initiate Phase 1 trials for BLU-701 in 2H 2021 and BLU-222 in 1H 2022, and disclose topline data for AYVAKIT's PIONEER trial in mid-2022.
Positive Outlook
- Present preclinical data supporting combination of BLU-945 and BLU-701 in treatment-naïve EGFR-driven NSCLC in the second half of 2021.
- Initiate a Phase 1 trial of BLU-701 in patients with treatment-resistant EGFR-driven NSCLC in the second half of 2021.
- Initiate a Phase 1 trial of BLU-222, a CDK2 inhibitor targeting cyclin-E aberrant cancers, in the first half of 2022.
- Disclose topline data for the registration-enabling Part 2 of the PIONEER trial of AYVAKIT in non-advanced systemic mastocytosis in mid-2022.